These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1240 related articles for article (PubMed ID: 33762954)

  • 41. Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic.
    Vallianou NG; Tsilingiris D; Christodoulatos GS; Karampela I; Dalamaga M
    Metabol Open; 2021 Jun; 10():100096. PubMed ID: 34056571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The journey of antimalarial drugs against SARS-CoV-2: Review article.
    Sarhan AA; Ashour NA; Al-Karmalawy AA
    Inform Med Unlocked; 2021; 24():100604. PubMed ID: 34028468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Directly Acting Antivirals for COVID-19: Where Do We Stand?
    Teoh SL; Lim YH; Lai NM; Lee SWH
    Front Microbiol; 2020; 11():1857. PubMed ID: 32849448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes.
    Brüssow H
    Environ Microbiol; 2021 Nov; 23(11):6364-6376. PubMed ID: 34519154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19.
    Banerjee S; Banerjee D; Singh A; Kumar S; Pooja D; Ram V; Kulhari H; Saharan VA
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predicted occurrence, ecotoxicological risk and environmentally acquired resistance of antiviral drugs associated with COVID-19 in environmental waters.
    Kuroda K; Li C; Dhangar K; Kumar M
    Sci Total Environ; 2021 Jul; 776():145740. PubMed ID: 33647647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Theory and reality of antivirals against SARS-CoV-2.
    Zhao B; Yang TF; Zheng R
    World J Clin Cases; 2021 Aug; 9(23):6663-6673. PubMed ID: 34447813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Repurposing current therapeutic regimens against SARS-CoV-2 (Review).
    K Konstantinidou S; P Papanastasiou I
    Exp Ther Med; 2020 Sep; 20(3):1845-1855. PubMed ID: 32782493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?
    Franczyk B; Rysz J; Miłoński J; Konecki T; Rysz-Górzyńska M; Gluba-Brzózka A
    Pharmaceuticals (Basel); 2022 Jun; 15(6):. PubMed ID: 35745658
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of Tox21 Screening Data to Evaluate the COVID-19 Drug Candidates for Their Potential Toxic Effects and Related Pathways.
    Sakamuru S; Huang R; Xia M
    Front Pharmacol; 2022; 13():935399. PubMed ID: 35910344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.
    Biswas M; Sawajan N; Rungrotmongkol T; Sanachai K; Ershadian M; Sukasem C
    Front Pharmacol; 2022; 13():835136. PubMed ID: 35250581
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy.
    Kumar S; Saurabh MK; Maharshi V; Saikia D
    J Pharm Bioallied Sci; 2021; 13(2):163-171. PubMed ID: 34349475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches.
    Raja RK; Nguyen-Tri P; Balasubramani G; Alagarsamy A; Hazir S; Ladhari S; Saidi A; Pugazhendhi A; Samy AA
    Appl Nanosci; 2023; 13(1):65-93. PubMed ID: 34131555
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review.
    Andrade BS; Rangel FS; Santos NO; Freitas ADS; Soares WRA; Siqueira S; Barh D; Góes-Neto A; Birbrair A; Azevedo VAC
    Front Pharmacol; 2020; 11():590598. PubMed ID: 33390967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutics for COVID-19 and post COVID-19 complications: An update.
    Basu D; Chavda VP; Mehta AA
    Curr Res Pharmacol Drug Discov; 2022; 3():100086. PubMed ID: 35136858
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.
    Sohag AAM; Hannan MA; Rahman S; Hossain M; Hasan M; Khan MK; Khatun A; Dash R; Uddin MJ
    Drug Dev Res; 2020 Dec; 81(8):919-941. PubMed ID: 32632960
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters.
    Roy Chattopadhyay N; Chatterjee K; Banerjee A; Choudhuri T
    Virusdisease; 2020 Dec; 31(4):479-489. PubMed ID: 33200085
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials.
    Venkadapathi J; Govindarajan VK; Sekaran S; Venkatapathy S
    Front Mol Biosci; 2021; 8():637378. PubMed ID: 34179072
    [TBL] [Abstract][Full Text] [Related]  

  • 59. nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics.
    Kabir MT; Uddin MS; Hossain MF; Abdulhakim JA; Alam MA; Ashraf GM; Bungau SG; Bin-Jumah MN; Abdel-Daim MM; Aleya L
    Front Cell Dev Biol; 2020; 8():616. PubMed ID: 32754599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.
    Kumar S; Basu M; Ghosh P; Pal U; Ghosh MK
    Genes Dis; 2023 Jul; 10(4):1402-1428. PubMed ID: 37334160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.